OTHER GLIPTINS EXPECTED ARE
Dutogliptin (being developed by Phenomix Corporation),Phase III
Gemigliptin (being developed by LG Life Sciences,Korea)
LONGER THE BELT , LESSER THE LIFE SPAN!
22 December, 2010
ALOGLIPTIN - ONE MORE EXPECTED IN
Alogliptin (codenamed SYR-322) is an investigational anti-diabetic drug in the DPP-4 inhibitor class, being developed by Takeda Pharmaceutical Company. Takeda has submitted a New Drug Application for alogliptin to the U.S. Food and Drug Administration, after positive results from Phase III clinical trials.
OTHER GLIPTINS EXPECTED ARE
Dutogliptin (being developed by Phenomix Corporation),Phase III
Gemigliptin (being developed by LG Life Sciences,Korea)
OTHER GLIPTINS EXPECTED ARE
Dutogliptin (being developed by Phenomix Corporation),Phase III
Gemigliptin (being developed by LG Life Sciences,Korea)
Subscribe to:
Post Comments (Atom)
The moment somebody says alogliptin, what i remember is that the IM happend in Goa and i missed it.
ReplyDeleteJust another DPP4 I, let's wait for the results.
you remeber missing the meeting or missing out on goa? for a teetotaler like you it doesnt make any difference right??
ReplyDelete